A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
Key facts
- Where
- Białystok, Bydgoszcz, Gdansk, Katowice, Krakow, Łódź, Lublin, Poznań, Rzeszów, Szczecin, Warsaw, Wrocław és Zabrze, LengyelországSee the 14 sites
- Phase
- 3. fázis
Where in Lengyelország
- Uniwersytecki Dziecięcy Szpital Kliniczny im. Ludwika Zamenhofa w BiałymstokuBiałystok, LengyelországTaking people
- Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w BydgoszczyBydgoszcz, LengyelországTaking people
- Medical University Of GdanskGdansk, LengyelországTaking people
- Uniwersyteckie Centrum Kliniczne w GdańskuGdansk, LengyelországTaking people
- Górnośląskie Centrum Zdrowia DzieckaKatowice, LengyelországTaking people
- Uniwersytecki Szpital Dzieciecy w KrakowieKrakow, LengyelországTaking people
- Centralny Szpital Kliniczny Uniwersytetu Medycznego w ŁodziŁódź, LengyelországTaking people
- Uniwersytecki Szpital Dziecięcy w LublinieLublin, LengyelországTaking people
- Szpital Kliniczny Uniwersytetu Medycznego im. Karola Marcinkowskiego w PoznaniuPoznań, LengyelországTaking people
- Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w RzeszowieRzeszów, LengyelországTaking people
- Uniwersytecki Szpital Klinicznym Nr 1 Pomorskiego Uniwersytetu MedycznegoSzczecin, LengyelországTaking people
- Instytut Pomnik Centrum Zdrowia DzieckaWarsaw, LengyelországTaking people
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we WrocławiuWrocław, LengyelországTaking people
- Samodzielny Publiczny Szpital Kliniczny Nr 1 Im.Prof.Stanislawa Szyszko Slaskiego Uniwersytetu Medycznego W KatowicachZabrze, LengyelországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Of Gdansk
- Trial code
- EU 2024-514635-26-00
- Record updated
- 2025. június 5.
- Original description
1. The possibility of individualizing the treatment of malignant liver tumors in children by classifying them into different groups according to the stage of the disease; 2. The possibility of reducing the occurrence of treatment side effects without significantly affecting the cure rate; 3. Improvement of curability, where current therapy is still not effective enough; 4. Selection of the most effective methods of surgical treatmentRead full original descriptionShow less
1. The possibility of individualizing the treatment of malignant liver tumors in children by classifying them into different groups according to the stage of the disease; 2. The possibility of reducing the occurrence of treatment side effects without significantly affecting the cure rate; 3. Improvement of curability, where current therapy is still not effective enough; 4. Selection of the most effective methods of surgical treatment
Inclusion: Clinically signs of Hepatoblastoma or Hepatocarcinoma (malignant tumors of the liver) + liver tumor; Age under 30; Signing informed consent to participate in the Study.
Exclusion: Previously or currently receiving chemotherapy treatment; Recurrence of the disease; Condition after organ transplantation; Uncontrolled generalized infection; Inability to conduct the Study in accordance with the Protocol; Other Associated Cancer; Pregnancy or breastfeeding.